¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"phytanic acid storage syndrome"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® deoxyribonucleic acid (DNA) ÇÑ±Û µ¥¿Á½Ã¸®º¸ÇÙ»ê
¼³¸í   
  ÇÙ»êÀÇ ÀÏÁ¾À¸·Î DNA¶ó°íµµ ÇÑ´Ù. DeoxyribonucleotideÀÇ ÁßÇÕüÀ̸ç À¯ÀüÀÚÀÇ È­ÇÐÀû º»Ã¼ÀÌ´Ù. RNA¹ÙÀÌ·¯½º ÀÌ¿ÜÀÇ ¸ðµç »ý¹°Àº DNA¸¦ À¯ÀüÀڷΠÁö´Ï°í ÀÖ´Ù. µð¿Á½Ã¸®º¸´ºÅ¬·¹¿ÀƼµå(deoxyribonucleotide)´Â ¿°±â¿Í ´ç(2'-deoxy-D-ribose)°ú ÀλêÀ¸·Î ÀÌ·ç¾îÁø´Ù. ¿°±â´Â ¾Æµ¥´Ñ(adenine), ±¸¾Æ´Ñ(guanine), Æ¼¹Î(thymine)¹× ½ÃÅä½Å(cytosine)ÀÇ 4°¡ÁöÀ̸ç, À̰ÍÀº ´ç¿¡ ºÎÂøµÇ¾î ÀÖ´Ù. Àλ꠿ª½Ã ´çÀÇ ÇÑ ºÎºÐ¿¡ ºÎÂøµÇ¾î ÀÖ´Ù. ÀÌ deoxyribonucleotideÀÇ ´çÀº ´Ù¸¥ deoxy- ribonucleotideÀÇ ´ç°ú ÀλêÀ» »çÀÌ¿¡ ³õ°í °áÇÕÀ» ÇϰԠµÇ¾î ÇϳªÀÇ ±ä »ç½½À» Çü¼ºÇϰԠµÈ´Ù. Áï ´ç°ú ÀλêÀÌ ÁÖÃàÀÌ µÇ¾î¼­ deoxyribonucleotideÀÇ ±ä »ç½½À» ¸¸µç´Ù. 
  
  ÀÌ deoxyribonucleotideÀÇ »ç½½ µÎ °³´Â °¢°¢ deoxyribonucleotide¿¡ ºÎÂøµÇ¾î Àִ ¿°±âµéÀÌ °áÇÕÀ» ÇÏ¿© µÎ °³ÀÇ »ç½½ÀÌ °áÇյǾî Àִ ÀÌÁß³ª¼± ±¸Á¶¸¦ ¸¸µé°Ô µÈ´Ù. 4°¡Áö ¿°±â ¾Æµ¥´ÑÀº Æ¼¹Î°ú °áÇÕÀ» Çϰí, ½ÃÅä½Å°ú °áÇÕÀ» ÇϰԠµÈ´Ù. Áï ´ç°ú ÀλêÀº ±ä »ç½½À» ¸¸µå´Â ¿ªÇÒÀ» ÇÏ°í ±ä »ç½½¿¡ ºÎÂøµÈ ¿°±âµéÀÇ °áÇÕ¿¡ ÀÇÇØ¼­ µÎ °³ÀÇ ±ä »ç½½Àº ¼­·Î ºÙ¾î¼­ ÀÌÁß³ª¼± ±¸Á¶¸¦ ¸¸µç´Ù.
  
  DNAÀÇ À¯ÀüÁ¤º¸´Â ¿°±â¿¡ ÀúÀåµÈ´Ù. 4°³ÀÇ ¿°±âÀÇ Á¶ÇÕ°ú ¹è¿­ÀÌ À¯ÀüÁ¤º¸¸¦ º¸°üÇϴ ÇϳªÀÇ ¾ÏÈ£ ¿ªÇÒÀ» ÇàÇϰԠµÈ´Ù.
  
  
¿µ¹® retinoic acid ÇÑ±Û ·¹Æ¼³ë»ê
¼³¸í   
  C20H28O2. ºñŸ¹Î AÀÇ ¾ËÄڿñ⸦ ¾Ëµ¥È÷µå·Î »êÈ­ÇÑ ÈÄ ´Ù½Ã Ä«¸£º¹½Ç»êÀ¸·Î »êÈ­ÇÏ¿© ¾òÀº »ê. ¹ß»ýÁßÀÇ ¼¼Æ÷¿¡ ÀÛ¿ëÇÏ¿© ÇüŸ¦ ¸¸µå´Âµ¥ °ü¿©ÇÑ´Ù.
¿µ¹® ribonucleic acid ÇÑ±Û ¸®º¸ÇÙ»ê
¼³¸í   
  Ribonucleotide monomer·Î ÀÌ·ç¾îÁø ÇÙ»êÀ¸·Î ¿°±â, ´ç, ÀλêÀ¸·Î ±¸¼ºµÈ´Ù. ¿°±â´Â adenine, guanine, cytosine, uracilÀÇ 4Á¾·ù°¡ ÀÖÀ¸¸ç, ´çÀº 5ź´çÀÌ´Ù. RNA´Â DNA¸¦ ÁÖÇüÀ¸·Î ÇÏ¿© »óº¸ÀûÀ¸·Î °áÇÕ, Çü¼ºµÇ¸ç ´Ü¹éÁúÀ» ¸¸µé¾î³»´Â µ¥¿¡ ÀÖ¾î Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù.
  
  Àü·É RNA(mRNA)´Â ´Ü¹éÁú ÇÕ¼º¿¡ À־¡À報⺻ÀÌ µÇ´Â DNAÀÇ ¼­¿­À» »óº¸ÀûÀ¸·Î ¿Å°Ü ¹Þ¾Æ Àü´ÞÇϴ Àü·É±¸½ÇÀ» Çϴ RNA. ¸®º¸¼Ø RNA(rRNA) ¸®º¸¼ØÀ» Çü¼ºÇϴ 4°¡Áö RNA»ç½½(28S, 18S, 5.8S, 5S·Î ±¸¼º). Àü´Þ RNA(tRNA) Æ¯Á¤ ¾Æ¹Ì³ë»êÀ» ÇÑÂÊ ³¡¿¡ Áö´Ï°í »óº¸Àû ¼­¿­ÀÇ mRNA¿Í ÀϽÃÀû °áÇÕÀ» ÀÌ·ç¸ç ´Ü¹éÁú ÇÕ¼º¿¡ Á÷Á¢ ±â¿©Çϴ RNAÀÌ´Ù.
¿µ¹® acid ÇÑ±Û »ê
¼³¸í   
  ¹°¿¡ ³ì¾ÒÀ» ¶§ ÀÌ¿ÂÈ­ÇÏ¿© ¼ö¼Ò ÀÌ¿ÂÀ» ¸¸µå´Â ¹°Áú. ½Å¸ÀÀÌ ³ª°í Ã»»ö ¸®Æ®¸Ó½º Á¾À̸¦ ºÓ°Ô º¯È­½ÃŰ¸ç ¿°±â¿ÍÀÇ ÁßÈ­ ¹ÝÀÀ¿¡ ÀÇÇÏ¿© ¹°°ú ¿°À» ¸¸µé°í ÀÌ¿ÂÈ­ ¿­¿¡¼­ ¼ö¼Òº¸´Ù ¾Õ¿¡ Àִ ±Ý¼Ó°ú ¹ÝÀÀÇÏ¿© ¿°À» ¸¸µé¸é¼­ ¼ö¼Ò¸¦ ¹ß»ý½ÃŲ´Ù. ¼ö¼Ò ¿øÀÚ¸¦ ÀÌ¿ÂÈ­Çϴ ÈûÀÇ °­¾à¿¡ µû¶ó °­»ê°ú ¾à»êÀ¸·Î ³ª´¶´Ù.
¿µ¹® acetic acid ÇÑ±Û ¾Æ¼¼Æ®»ê, ÃÊ»ê
¼³¸í   
  ºÐÀÚ½ÄÀº C2H4O2, ºÐÀÚ·® 60.05ÀÇ Àú±Þ Áö¹æ»êÀÌ´Ù. CH3COOHÀÇ ±¸Á¶½ÄÀ» °¡Áø ¹«»ö¾×ü·Î 16.7¡É¿¡¼­ ³ì°í 118.0¡É¿¡¼­ ²ú´Â´Ù. ½ÄÃÊÀÇ ½Å¸ÀÀ» ³»´Â °ÍÀ̰í, ³óÃàµÈ °ÍÀ» ºùÃÊ»êÀ̶ó ÇÑ´Ù. »ó¿Â¿¡¼­´Â ¾×üÀ̸砼ö¿ë¾×Àº ¾à»ê¼ºÀÌ´Ù. »ýü³»¿¡¼­´Â ÀϹÝÀûÀ¸·Î ¾Æ¼¼Æ¿ CoA·Î Á¸ÀçÇϸ砾Ƽ¼Æ¿±âÀÇ °ø±Þ¿øÀÌ µÇ´Â ¿Ü¿¡ Áö¹æ»êÀ̳ª ½ºÅ×·ÎÀ̵堵îÀÇ »ý¼ºÀç·á·Î Áß¿äÇÏ´Ù. ¾Æ¼¼Æ¿ CoA·ÎºÎÅʹ ÄÉÅæÃ¼°¡ ÇÕ¼ºµÇ¸ç Á¶Á÷ÀÇ ¿¡³ÊÁö¿øÀÌ µÈ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • phytanic acid storage disease
    ÇÇź»êÃàÀûº´
  • copper storage disease
    ±¸¸®ÃàÀûº´
  • cystine storage disease
    ½Ã½ºÆ¾ÃàÀûº´
  • cholesteryl ester storage disease
    ÄÝ·¹½ºÅ×·Ñ¿¡½ºÅ׸£ÃàÀûº´
  • glycogen storage disease
    ±Û¸®ÄÚ°ÕÃàÀûº´, ´ç¿øÃàÀûº´
  • iron-storage disease
    öÃàÀûÁúȯ
  • lipid storage disease
    ÁöÁúÃàÀûº´
  • lysosomal storage disease
    ¿ëÇØ¼ÒüÃàÀûº´, ¸®¼ÒÁ»ÃàÀûº´
  • storage
    1. ÃàÀû 2. º¸Á¸, ÀúÀå 3. ±â¾ïÀåÄ¡
  • storage disease
    ÃàÀûº´
  • storage iron
    ˜ˌ̦
  • storage-type
    ÃàÀûÇü
  • virtual storage
    °¡»ó±â¾ïÀåÄ¡
  • anthranilic acid
    ¾ÈÆ®¶ó´Ò»ê
  • anti-double stranded deoxyribonucleic acid antibody
    Ç×ÀÌÁß°¡´ÚDNAÇ×ü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • storage disease
    ÃàÀûº´
  • storage iron
    ˜ˌ̦
  • storage-type
    ÃàÀûÇü
  • storage
    ÃàÀû, º¸Á¸, ÀúÀå
  • acid fastness
    Ç׻꼺
  • acid rain
    »ê¼ººñ
  • acid
    Ȑ
  • acetic acid
    ¾Æ¼¼Æ®»ê, ÃÊ»ê
  • acetoacetic acid
    ¾Æ¼¼Å侯¼¼Æ®»ê
  • amino acid
    ¾Æ¹Ì³ë»ê
  • anti-double stranded deoxyribonucleic acid antib antibody
    Ç×ÀÌÁß°¡´Úµð¿£¿¡ÀÌÇ×ü
  • arachidonic acid
    ¾Æ¶ó۵·»ê
  • arsenic acid
    ºñ»ê
  • ascorbic acid
    ¾Æ½ºÄÚ¸£ºó»ê
  • calcium ethylenediaminetetraacetic acid
    Ä®½·¿¡Æ¿·»µð¾Æ¹Î»ç¾Æ¼¼Æ®»ê
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • copper storage disease
    ±¸¸®ÀúÀ庴
  • cystine storage disease
    ½Ã½ºÆ¾ÃàÀûº´
  • glucose storage disease
    ´çÃàÀûº´
  • glycogen storage disease
    ´ç¿øÃàÀûº´
  • lipid storage disease
    ÁöÁúÃàÀûº´
  • lysosomal storage disease
    ¸®¼Ò¼ØÃàÀûº´, ¿ëÇØ¼ÒüÃàÀûº´
  • neuronal storage disease
    ½Å°æ¼¼Æ÷ÀúÀ庴
  • storage disease
    ÃàÀûº´
  • storage iron
    ˜ˌ̦
  • storage
    ÃàÀû, º¸Á¸, ÀúÀå
  • storage-type
    ÃàÀûÇü
  • stock organism storage
    º¸Á¸¼¼±ÕÀúÀå
  • virtual storage
    °¡»ó±â¾ïÀåÄ¡
  • acid
    Ȑ
  • acetic acid
    ¾Æ¼¼Æ®»ê, ÃÊ»ê
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Dorfman-Chanarin syndrome = neutral lipid storage disease
    Áß¼ºÁö¹æÃàÀûÁõ
  • glucose storage disease
    ´çÃàÀûÁúȯ.
  • glycogen storage disease
    ±Û¸®ÄÚ°ÕÃàÀû Áúȯ.
  • glycogen storage disease
    ´ç¿ø ÃàÀûÁúȯ(ÓØê«õëîÝòðü´)
  • glycogen storage disease
    ±Û¸®ÄÚ°ÕÃàÀûÁúȯ
  • image storage
    ¿µ»óÀúÀå<--ÃàÀû
  • 3,4-dihydroxyphenylacetic acid, homogentisic acid
    3,4-µðÈ÷µå·Ï½ÃÆä´Ò ¾Æ¼¼Æ¾»ê= È£¸ð°Õƾ»ê
  • abietinic acid ; abietic acid
    ¾Æºñ¿¡Æ¾»ê.
  • acetic anhydride-acetic acid-sulfuric acid
    ¹«¼öÃÊ»ê-ÃÊ»ê-Ȳ»ê
  • acid-base balance=acid-base equilibrium
    »ê¿°±â ÆòÇü(¡­øÁû¬)
  • hydroxyindoleacetic acid, 5-hydroxyindoleacetic acid (5-hiaa)
    5-ÇÏÀ̵å·Ï½ÃÀε¹¾Æ¼¼Æ®»ê
  • acid aspiration syndrome
    À§»ê ÈíÀÔ ÁõÈıº
  • Browns syndrome->superior oblique tendon sheath syndrome
    ºê¶ó¿îÁõÈıº
  • Cowdens syndrome = multiple hamartoma syndrome
    ´Ù¹ß¼º °ú¿ÀÁ¾ ÁõÈıº
  • ICE syndrome=iridocorneal endothelial syndrome
    ȫä°¢¸·³»ÇÇÁõÈıº
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ceroid storage disease
    ¼¼·ÎÀ̵åÃàÀûÁúȯ.
  • copper storage disease
    µ¿ÀúÀåÁúȯ(ÔÞîÍíúòðü´).
  • cystine storage disease
    ½Ã½ºÆ¾(ÃàÀû)º´ (¡­õëîÝÜ»).
  • food storage
    ½ÄǰÀúÀå.
  • glucose storage disease
    ´çÃàÀûÁúȯ.
  • glycogen storage disease
    ±Û¸®ÄÚ°ÕÃàÀûÁúȯ
  • glycogen storage disease
    ±Û¸®ÄÚ°ÕÃàÀû Áúȯ.
  • glycogen storage disease
    ´ç¿ø ÃàÀûÁúȯ(ÓØê«õëîÝòðü´)
  • image storage
    ¿µ»óÀúÀå<--ÃàÀû
  • lipid storage disease
    ÁöÁúÃàÀûÁõ
  • lipid storage disease
    ÁöÁúÃàÀûÁõ.
  • lysosomal storage diseaes
    ¸®¼Ò¼Ø¼º ÃàÀûº´(¡­ õëîÝÜ»)
  • lysosomal storage disease
    ¸®¼Ò¼Ø ÃàÀûÁõ
  • neuronal storage disease
    ½Å°æ¼¼Æ÷¼ºÀúÀåÁúȯ(¡­á¬øààõîÍíúòðü´)
  • stock organism storage
    º¸Á¸¼¼±ÕÀúÀå
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Metabolic defect of amino acid (Alkaptonuria)
    ¾Æ¹Ì³ë»ê´ë»ç°áÇÔ(¾Ëİſ´¢Áõ)
    [¿¾ ¿ë¾î] ¾Æ¹Ì³ë»ê´ë»ç°áÇÔ(¾Ëİſ´¢Áõ)
  • Metabolic defect of nucleic acid (Purinemia)
    ÇÙ»ê´ë»ç°áÇÔ(Ç»¸°Ç÷Áõ)
    [¿¾ ¿ë¾î] ÇÙ»ê´ë»ç°áÇÔ(Ç»¸°Ç÷Áõ)
  • Metabolic defect of steroid (Adrenogenital syndrome)
    ½ºÅ×·ÎÀ̵å´ë»ç°áÇÔ(ºÎ½Å»ý½Ä±âÁõÈıº)
    [¿¾ ¿ë¾î] ½ºÅ×·ÎÀ̵å´ë»ç°áÇÔ(ºÎ½Å»ý½Ä±âÁõÈıº)
  • Syndrome
    ÁõÈıº
    [¿¾ ¿ë¾î] ÁõÈÄ
  • Syndrome (Down)
    ÁõÈıº (´Ù¿îÁõÈıº)
    [¿¾ ¿ë¾î] ÁõÈÄ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Loeffler's syndrome
    ·ÚÇ÷¯ÁõÈıº
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • phytanic acid storage syndrome
    ÇÇź»ê(ß«) ÃàÀû ÁõÈıº(õëîÝñøý¦ÏØ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • phytanic acid
    ÇÇź»ê(ß«)
  • glycogen storage disease
    ±Û¶óÀÌÄÚÀü ÀúÀå Áúȯ(îÍíúòðü´)
  • lipid storage disease
    ÁöÁúÀúÀåÁúȯ(ò·òõîÍíúòðü´)
  • lysosomal storage disease
    ¶óÀ̼ÒÁ»³»(Ò®) ÀúÀåÁúȯ(îÍíúòðü´)
  • mucopolysaccharide storage disease
    ¹ÂÄÚ´Ù´çÁú(ÒýÓØòõ)ÀúÀåÁúȯ(îÍíúòðü´)
  • storage mRNA
    ÀúÀå(îÍíú) mRNA
  • Crigler-Najjar syndrome
    Å©¸®±Û·¯-³ª¾ß¸£ ÁõÈıº(ñøý¦ÏØ)
  • Down's syndrome
    ´Ù¿î ÁõÈıº(ñøý¦ÏØ) (ÔÒ) mongolism
  • ectopic hormone syndrome
    À̼Ò(ì¶á¶) È£¸£¸ó ÁõÈıº(ñøý¦ÏØ)
  • Fanconi's syndrome
    ÆÇÄÚ´Ï ÁõÈıº(ñøý¦ÏØ)
  • fragile X syndrome
    Ãë¾à(öªå°) X ÁõÈıº(ñøý¦ÏØ)
  • general adaptation syndrome
    ÀÏ¹Ý ÀûÀÀ ÁõÈıº(ìéÚõ îêëëñøý¦ÏØ)
  • Hunter's syndrome
    ÇåÅÍ ÁõÈıº(ñøý¦ÏØ)
  • Hurler's syndrome
    Çæ·¯ ÁõÈıº(ñøý¦ÏØ)
  • Lesch-Nyhan syndrome
    ·¹½¬-´ÏÇÑ ÁõÈıº(ñøý¦ÏØ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • glycogen storage disease
    ±Û¸®ÄÚ°Õ ÃàÀûÁúȯ
  • long-term storage
    Àå±âÀúÀå(ÀåÄ¡)
  • short-term storage
    ´Ü±âÀúÀå(ÀåÄ¡)
  • storage
    ÃàÀû, º¸Á¸, ÀúÀå
  • storage disease
    ÃàÀûÁõ
  • storage oscilloscope
    ÀúÀå½Ä¿À½Ç·Î½ºÄÚÇÁ
  • storage tube
    ÀúÀå°ü
  • virtual storage
    °¡»ó±â¾ïÀåÄ¡
  • acetic acid
    ÃÊ»ê
  • acid
    »ê, »ê¼ºÀÇ
  • acid base balance
    »ê¿°±â ÆòÇü
  • acid fast bacteria
    Ç׻꼺 ¼¼±Õ
  • deoxyribonucleic acid
    Å׿Á½Ã¸®º¸ÇÙ»ê
  • folic acid
    Æú»ê, ¿±»ê
  • lactic acid
    ¶ôÆ®»ê, Á¥»ê, À¯»ê
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MS Maffuci syndrome; maladjustment score; mandibular series; Marfan syndrome; Marie-Strumpell [syndrome...
PA panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'...
VIS vaginal irrigation smear; venous insufficiency syndrome; vertebral irritation syndrome; visible; vis...
VS vaccination scar; vaccine serotype; vagal stimulation; vasospasm; venesection; ventricular septum; v...
CS calf serum; campomelic syndrome; carcinoid syndrome; cardiogenic shock; caries-susceptible; carotid ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CESD Cholesterol ester storage disease
GSD Glycogen Storage Disease
GSDII Glycogen Storage Disease type II
GSD 1a Glycogen storage disease type 1a
GSD I Glycogen storage diseases type I
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • lipid storage
    Áö¹æ ÀúÀå
    Áö¹æ ¼¼Æ÷°¡ ´ã´çÇÏ´Â ±â´ÉÀ¸·Î ü³»¿¡ Èí¼öµÈ Áö¹æÀº ų·Î¹ÌÅ©·ÐÀÇ ÇüÅ·Πü¼øÈ¯À» ÇÏ°Ô µÇ¸ç, Áö¹æ Á¶Á÷ÀÇ ¸ð¼¼Ç÷°ü¿¡ À̸£¸é ³»ÇÇ ¼¼Æ÷ÀÇ ´çÁöÁú ¸®ÆÄ¾ÆÁ¦ÀÇ ÀÛ¿ëÀ¸·Î À¯¸® Áö¹æ»ê°ú ´Ü´ç·ù·Î ºÐÇØµÇ¾î Áö¹æ ¼¼Æ÷¿¡ ÀÇÇØ ´Ü¼ø È®»êÀ¸·Î ¼·ÃëµÈ´Ù. ÀÌ Áö¹æ»êÀº Áö¹æ ÇÕ¼º È¿¼Ò¿¡ ÀÇÇÏ¿© Áß¼º Áö¹æÀ¸·Î ÇÕ¼ºµÇ¸ç Áö¹æ ºÐÇØ È¿¼Ò¸¦ ¾ïÁ¦ÇÏ¿© Áö¹æÀ» ÃàÀû½ÃŲ´Ù.
  • neuronal storage disease
    ½Å°æ ÃàÀûÁõ
  • storage
    ÃàÀû, º¸Á¸, ÀúÀå
    Ä¡°ú º¸Ã¶ ¿µ¿ª¿¡¼­´Â °¡Ã¶ ÀÇÄ¡ÀÇ ºÐ½Ç, ÆÄ¼Õ, ¹× º¯ÇüÀ» ¿¹¹æÇϱâ À§ÇÏ¿© ¾ÈÀüÇÑ Àå¼ÒÀÎ ¹° ¼Ó¿¡ µÎ´Â °Í.
  • storage of drug
    ¾à¹°ÀÇ º¸°ü
  • storage pool disease
    ÀúÀåÁ¶º´
    ÀÀÁýÁ¦, ¿¡Çdz×ÇÁ¸°, ¿ÜÀμº ADP, Æ®·Òºó µî¿¡ ¹ÝÀÀÇÏ¿© ADP¸¦ ¹æÃâÇÏ´Â Ç÷¼ÒÆÇ ±â´É ºÎÀü¿¡ ÀÇÇÑ Ç÷¾× ÀÀ°í Àå¾Ö, °¡º­¿î ÃâÇ÷ Áõ»ó, ÃâÇ÷ ½Ã°£ Áö¿¬, ±³¿øÁúÀ̳ª Æ®·Òºó¿¡ ´ëÇÑ ÀÀÁý ¹ÝÀÀÀÇ °¨Å𸦠Ư¡À¸·Î ÇÑ´Ù.
  • acid aspiration syndrome
    À§»ê ÈíÀÔ ÁõÈıº
  • 11-amino acid polypeptide
    11-¾Æ¹Ì³ë»ê Æú¸® ÆéŸÀ̵å
  • 5-hydroxyindoleacetic acid
    5-ÇÏÀ̵å·Ï½Ã Àε¹ ¾Æ¼¼Æ½ ¿¡½Ãµå
    5-HT ´ë»ç »ê¹°ÀÇ ÇϳªÀÌ´Ù. ¾Ç¼º Á¾¾ç, ¹Ù³ª³ª ¼·Ãë ¹× reser
  • 9-amino acid peptide
    9-¾Æ¹Ì³ë»ê ÆéŸÀ̵å
  • abietolic acid
    ¾Æºñ¿¡Åç»ê
    C20H28O7. °áÁ¤¼º »ê¼º ¼öÁö.
  • acetic acid solution
    ¾Æ¼¼Æ® »ê ¿ë¾×
  • acetoacetic acid test
    ¾Æ¼¼Åä ÃÊ»ê ½ÃÇè
  • acetrizoic acid
    ¾Æ¼¼Æ®¶óÀÌÁ¶»ê
    ¹«ÃëÀÇ ¹é»ö ºÐ¸».
  • acid
    Żȸ¾×
  • acid alcohol
    »ê¼º ¾ËÄÚ¿Ã
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
phytanic acid storage disease A genetic disorder of the fatty acid phytanic acid which accumulates and causes a number of progressive problems including polyneuritis (inflammation of numerous nerves), diminishing vision (due to retinitis pigmentosa), and wobbliness (ataxia) caused by damage to the cerebellar portion of the brain (cerebellar ataxia).
(12 Dec 1998)
disease, phytanic acid storage A genetic disorder of the fatty acid phytanic acid which accumulates and causes a number of progressive problems including polyneuritis (inflammation of numerous nerves), diminishing vision (due to retinitis pigmentosa), and wobbliness (ataxia) caused by damage to the cerebellar portion of the brain (cerebellar ataxia).(refsum's disease)
(12 Dec 1998)
phytanic acid <chemical> 3,7,11,15-tetramethylhexadecanoic acid. A 20-carbon branched chain fatty acid. In phytanic acid storage disease (refsum disease) this lipid may comprise as much as 30% of the total fatty acids of the plasma. This is due to a phytanic acid alpha-hydroxylase deficiency.
Chemical name: Hexadecanoic acid, 3,7,11,15-tetramethyl-
(12 Dec 1998)
phytanic acid alpha-oxidase <enzyme> May be the genetic defect in refsum's disease
Registry number: EC 1.14.99.-
Synonym: phytanic acid alpha-hydroxylase
(26 Jun 1999)
brancher glycogen storage disease Type of glycogen storage disease, due to deficiency of amylo-1,4-1,6-transglucosidase (brancher enzyme).
Synonym: brancher deficiency glycogenosis, debrancher deficiency.
(05 Mar 2000)
glycogen storage disease <hepatology> A group of inherited metabolic disorders involving the enzymes responsible for the synthesis and degradation of glycogen. In some patients, prominent liver involvement is presented. In others, more generalised storage of glycogen occurs, sometimes with prominent cardiac involvement.
Synonym: glycogenosis
(12 Sep 2002)
glycogen storage disease type I <disease> An autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycaemia due to lack of glucose production.
Accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. Increased concentrations of lactic acid and hyperlipidemia appear in the plasma. Clinical gout often appears in early childhood.
Inheritance: autosomal recessive.
(12 Dec 1998)
glycogen storage disease type II <disease> Glycogenosis due to alpha-1,4-glucosidase (acid maltase) deficiency. It affects muscle, heart, and other organs.
(12 Dec 1998)
glycogen storage disease type III <disease> An autosomal recessive metabolic disorder due to deficient expression of amylo-1,6-glucosidase (one part of the glycogen debranching enzyme system).
The clinical course of the disease is similar to that of glycogen storage disease type I, but milder. Massive hepatomegaly, which is present in young children, diminishes and occasionally disappears with age. Levels of glycogen with short outer branches are elevated in muscle, liver, and erythrocytes. Six subgroups have been identified, with subgroups type IIIa and type IIIb being the most prevalent.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type IV <disease> An autosomal recessive metabolic disorder due to a deficiency in expression of branching enzyme (alpha-1,4-glucan-6-alpha-glucosyltransferase), resulting in an accumulation of abnormal glycogen with long outer branches. Clinical features are muscle hypotonia and cirrhosis. Death from liver disease usually occurs before age 2.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type V <disease> Glycogenosis due to muscle phosphorylase deficiency. Characterised by painful cramps following sustained exercise.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VI <disease> A hepatic glycogen storage disease in which there is an apparent deficiency of hepatic phosphorylase activity. However, studies have not been able to distinguish between phosphorylase deficiency and phosphorylase kinase deficiency in patients with hepatic glycogenosis.
(12 Dec 1998)
glycogen storage disease type VII <disease> An autosomal recessive muscle glycogen storage disease in which there is deficient expression of muscle phosphofructokinase activity, resulting in increased concentrations of glucose-6-phosphate and fructose-6-phosphate and low concentrations of fructose-1,6-diphosphate in muscle tissue.
Glycogen storage in muscle is increased, perhaps due to activation of glycogen synthase by accumulated glucose-6-phosphate. It has been proposed that shunting of glucose-6-phosphate and fructose-6-phosphate into the pentose phosphate pathway may result in increased synthesis of purines and pyrimidines, causing hyperuricaemia and gout.
Erythrocytes from patients may show decreased phosphofructokinase activity and 2,3-diphosphoglycerate deficiency. Exercise intolerance is present and severe congenital muscular dystrophy has been reported.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VIII <disease> An x-linked recessive hepatic glycogen storage disease resulting from lack of expression of phosphorylase-b-kinase activity. Symptoms are relatively mild; hepatomegaly, increased liver glycogen, and decreased leukocyte phosphorylase are present. Liver shrinkage occurs in response to glucagon.
Inheritance: X-linked recessive
(12 Dec 1998)
cholesterol ester storage disease A rare benign adult form of inherited lysosomal lipid storage disease that is due to deficiency of acid lipase. It results in an accumulation of neutral lipids, particularly cholesterol esters, within cells (particularly leukocytes, fibroblasts, and liver cells). It is an allelic variant of wolman disease.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Down's syndrome
    ´Ù¿î ÁõÈıº(Mongolism)
  • HunterRussel syndrome
    ÇåÅÍ ·¯¼¿ ÁõÈıº(À¯±â ¼öÀº Áßµ¶)
  • Reye('s) syndrome
    ¶óÀÌ ÁõÈıº(¼Ò¾Æ¿¡°Ô ÈçÈ÷ ÀÖ´Â ³úÀå¾Ö)
  • behcets syndrome
    º£ÀÌú´(´«,ÀÔÀÇ Á¡¸·,À½ºÎ¿¡ º´ÀÌ »ý±è)
  • empty nest syndrome
    (Á¤ÀÇ)¼ºÀåÇÑ ÀڽĵéÀÌ ´Ù ¶°³ª¹ö¸° ³ë³â ºÎºÎ¿¡°Ô ÈçÈ÷ ³ªÅ¸³ª´Â ÁõÈıº(Á¤½ÅÀû ºÒ¾ÈÁ¤°ú ¿ì¿ïÁõÀ» ¼ö¹ÝÇÏ´Â ÇãÅ»°¨)
  • general adaptation syndrome
    ¹üÀûÀÀ ÁßÈıº
  • highpressure nervous syndrome
    °í¾Ð ½Å°æ ÁõÈıº
  • postvietnam syndrome
    º£Æ®³² ÈÄ ÁõÈıº
  • premenstrual syndrome
    ¿ù°æÀü ÁõÈıº
  • respiratory distress syndrome
    (½Å»ý¾ÆÀÇ)È£Èí Àå¾Ö ÁõÈıº
  • syndrome
    ÁõÈıº;ÇൿÇü
  • storage
    ÀúÀå,º¸°ü,â°í,ÃàÀü
  • cold storage
    (¸ÔÀ» °ÍµîÀÇ)ÀïÀå;µ¿°á»óÅÂ;¹¦;¹¦Áö
  • control storage
    Á¦¾î±â¾ïÀåÄ¡
  • core storage
    ÀÚ½É ±â¾ï ÀåÄ¡
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á